Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve the Un-Audited Financial ....
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bafna Pharmaceuticals has informed the stock exchanges that its Board of Directors will meet on February 11, 2026, to consider and approve the Un-Audited Financial Results for the quarter ended December 31, 2025 (Q3 FY26). This is a routine regulatory intimation filed under SEBI LODR Regulation 29. The company has also confirmed that the trading window for designated persons remains closed from January 1, 2026 to February 13, 2026, both days inclusive, in line with insider trading rules. No financial figures or business updates are disclosed in this filing.
This is a procedural announcement with no direct impact on the stock price. Investors should watch the actual Q3 results on February 11, 2026, for revenue, profit, and margin trends that could influence sentiment.